ASH 2021 | MajesTEC-1: teclistamab for myeloma
Amrita Krishnan
• 15 Dec 2021
Amrita Krishnan, MD, City of Hope, Duarte, CA, gives a brief overview of advancements in multiple myeloma treatment, highlighting the MajesTEC-1 trial (NCT04557098), which is studying teclistamab, a BCMA-directed bispecific antibody, in patients with advanced refractory myeloma. Dr Krishnan describes the administration and side effects seen in the use of teclistamab, as well as the very promising deep responses seen in patients treated with this anti-myeloma drug. This interview took place at the 63rd ASH Annual Meeting and Exposition, Atlanta, 2021.
